Table 5 Characteristics of four patients who discontinued ADA because of sustained remission
Variable | Case 1 | Case 2 | Case 3 | Case 4 |
|---|---|---|---|---|
Sex | Female | Female | Female | Female |
Age, years | 38 | 63 | 69 | 80 |
Weight, kg | 54 | 42 | 53 | 62 |
Disease duration, years | 4 | 0.3 | 3.2 | 0.8 |
DAS28-ESR at baseline | 4.34 | 5.92 | 4.09 | 4.96 |
RF | 58 | < 5 | 35 | 80 |
ACPA | > 100 | < 0.6 | 59.2 | > 300 |
Stage | II | I | IV | II |
HAQ-DI at baseline | No data | 1.625 | 1.125 | 0.75 |
MTX mg/week | 8 | 6 | 8 | 6 |
Prior use of biologics | No | No | No | No |
Time until achievement of remission, months | 1 | 12 | 1 | 1 |
Continuation of remission, months | 29 | 12 | 12 | 34 |
DAS28-ESR at discontinuation of ADA | 0.97 | 2.11 | 1.46 | 2.50 |
HAQ-DI at discontinuation of ADA | No data | 0.75 | 0 | 0 |
First outcome | Flare at 6 months | Remission continued for 29 months | Flare at 8 months | Flare at 3 months |
Second outcome | Achieved remission 1 month after restarting ADA | No flare | No remission after restarting ADA | Achieved remission 1 month after restarting ADA |